Annual reports

Høyvik AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, Peng Q, Wangen-Riise R, Wiig E, Ma LW, Revheim ME, Juzeniene A (2025)
Optimizing [²¹²Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts
J Nucl Med (in press)
DOI 10.2967/jnumed.125.270444, PubMed 41043994

Pharo H, Vedeld HM, Wahlqvist R, Lind GE (2025)
Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol 2025;88:23-30
Eur Urol (in press)
DOI 10.1016/j.eururo.2025.07.028, PubMed 40998632

Pfefferle A, Malmberg KJ (2025)
Rewiring natural killer cells for next-generation cancer therapies
Cancer Cell (in press)
DOI 10.1016/j.ccell.2025.08.007, PubMed 40972573

Emaldi M, Rey-Iborra E, Alamillo-Maeso P, Pulido R, Nunes-Xavier CE (2026)
Analysis of the Functional Impact of Glycosylation on Immune Checkpoint Proteins
Methods Mol Biol, 2959, 55-72
DOI 10.1007/978-1-0716-4734-9_4, PubMed 41028258

Rey-Iborra E, Emaldi M, Madariaga M, Pulido R, Nunes-Xavier CE (2026)
3D Spheroids to Study the Impact of Immune Checkpoint Proteins in Solid Tumors
Methods Mol Biol, 2959, 141-156
DOI 10.1007/978-1-0716-4734-9_10, PubMed 41028264

Høyvik AJK, Stenberg VY, Liukaityte R, Repetto-Llamazares A, Peng Q, Wangen-Riise R, Wiig E, Ma LW, Revheim ME, Juzeniene A (2025)
Optimizing [²¹²Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts
J Nucl Med (in press)
DOI 10.2967/jnumed.125.270444, PubMed 41043994